SCHEMBL31040960

SCHEMBL31040960

Cc1ccc(OCC(=O)OC(C)(C)C)cc1N1CCC(=O)NC1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 8/20 0.65
▸ CRBN Q96SW2 8/20 0.65
▸ PSEN1 P49768 1/20 0.38
▸ PSEN2 P49810 1/20 0.38
▸ APH1B Q8WW43 1/20 0.38
▸ NCSTN Q92542 1/20 0.38
▸ APH1A Q96BI3 1/20 0.38
▸ PSENEN Q9NZ42 1/20 0.38
▸ RAB9A P51151 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ GPR84 Q9NQS5 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HPGD P15428 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31040967 0.92 DDB1 (0.65) DDB1CRBNPSEN1PSEN2APH1B
SCHEMBL31255428 0.87 DDB1 (0.48) DDB1CRBNALDH1A1HPGDHSD17B10
SCHEMBL31255309 0.86 DDB1 (0.49) DDB1CRBNRAB9AMEN1KMT2A
SCHEMBL23120752 0.85 DDB1 (0.51) DDB1CRBNRAB9AMEN1KMT2A
SCHEMBL29606738 0.85 DDB1 (0.51) DDB1CRBNRAB9AMEN1KMT2A
SCHEMBL30257619 0.83 DDB1 (0.62) DDB1CRBNPSEN1PSEN2APH1B
SCHEMBL30257675 0.83 DDB1 (0.64) DDB1CRBNPSEN1PSEN2APH1B
SCHEMBL31040954 0.81 DDB1 (0.54) DDB1CRBNMEN1KMT2AALDH1A1
SCHEMBL31255533 0.80 DDB1 (0.44) DDB1CRBNRAB9AMEN1KMT2A
SCHEMBL31255633 0.80 DDB1 (0.53) DDB1CRBNRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261416-A1 SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2024-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261416-A1 SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CRBN, CUL1, CUL5 DDB1 188/4885CRBN 1/4885PSEN1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback